Neoadjuvant sunitinib for surgically complex advanced renal cell cancer of doubtful resectability: initial experience with downsizing to reconsider cytoreductive surgery
- 15 January 2009
- journal article
- Published by Springer Nature in World Journal of Urology
- Vol. 27 (4), 533-539
- https://doi.org/10.1007/s00345-008-0368-7
Abstract
To evaluate neoadjuvant sunitinib in patients with synchronous metastatic renal cell cancer (mRCC) to downsize surgically complex tumours and reconsider cytoreductive surgery.Keywords
This publication has 27 references indexed in Scilit:
- Neoadjuvant targeted therapy and advanced kidney cancer: observations and implications for a new treatment paradigmBJU International, 2008
- Sunitinib for Treatment of Advanced Renal Cell Cancer: Primary Tumor ResponseClinical Cancer Research, 2008
- Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removedBJU International, 2007
- We Should Desist Using RECIST, at Least in GISTJournal of Clinical Oncology, 2007
- Effect of Vascular Normalization by Antiangiogenic Therapy on Interstitial Hypertension, Peritumor Edema, and Lymphatic Metastasis: Insights from a Mathematical ModelCancer Research, 2007
- Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: Is It Still Imperative in the Era of Targeted Therapy?Clinical Cancer Research, 2007
- Rapid vascular regrowth in tumors after reversal of VEGF inhibitionJournal of Clinical Investigation, 2006
- Should radical nephrectomy be performed in the face of surgically incurable disease?Current Opinion in Urology, 2000
- Renal cell carcinoma: should radical nephrectomy be performed in the presence of metastatic disease?Current Opinion in Urology, 1999
- En Bloc Aortic Resection for Bulky Metastatic Germ Cell TumorsJournal of Urology, 1995